(PharmaNewsWire.Com, August 25, 2019 ) According to the new market research report "Cell Surface Markers Market by Product (Antibody, PCR Array), Source (Mice, Rat), Cell Type (T cells, B cells, NK cell), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)), and End User (Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
Based on antibodies by source, the cell surface markers market is segmented into mice, rats, and other sources. In 2018, the mice segment is expected to account for the largest share of the cell surface markers market. This segment is also expected to grow at the highest CAGR during the forecast period primarily due to the cost-effectiveness offered by mice models as a source of antibody production.
The cell surface markers market, by cell type, is segmented into T cell surface markers, B cell surface markers, NK cell surface markers, monocyte cell surface markers, and other cell types. In 2018, the T cell surface markers segment is expected to account for the largest share of the cell surface markers market. The increasing use of these cell surface markers in research and diagnostics is expected to fuel the growth of this segment.
Browse and in-depth TOC on " Cell Surface Markers Market " 91 – Tables 40 - Figures 140 - Pages
Based on application, the cell surface markers market is segmented into research and clinical applications. In 2018, the research applications segment is expected to account for the largest share of the cell surface markers market. The large share of this segment can primarily be attributed to the rising public-private funding for cell surface marker-based research and the growing use of cell surface markers in cancer, stem cell, and HIV research.
Based on end user, the cell surface markers market is segmented into academic & research institutes, hospitals & clinical testing laboratories, and pharmaceutical & biotechnology companies. In 2018, the academic & research institutes segment is expected to account for the largest share of the cell surface markers market. The growing use of cell surface markers in cancer, stem cell, and HIV research; increasing number of cancer and stem cell research projects across the globe; and the rising public-private funding for cell surface marker-based research are the major factors driving the growth of this end-user segment.
Market growth in North America, the largest regional market for cell surface markers, is primarily driven by the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. The high growth of the Asian market can be attributed to the increasing number of life sciences research activities and government initiatives to boost the biotechnology and pharmaceutical industries in several Asian countries.
The cell surface markers market is highly fragmented in nature, with several big as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
